ERAS 3788
Alternative Names: ERAS-3788Latest Information Update: 02 Sep 2021
At a glance
- Originator The Regents of the University of California
- Developer Erasca
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 02 Sep 2021 Preclinical trials in Solid tumours in USA (unspecified route) prior to September 2021 (Erasca pipeline, September 2021)
- 02 Sep 2021 Pharmacokinetics data from preclinical studies in solid tumours released by Erasca
- 01 Sep 2021 Early research in Solid tumours in USA (unspecified route) prior to September 2021 (Erasca pipeline, September 2021)